Munster, P., Iannotti, N., Cho, D. C., Kirkwood, J. M., Villaruz, L. C., Gibney, G. T., … O’Day, S. (2024). Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Res Commun, 4(3), 785. https://doi.org/10.1158/2767-9764.CRC-24-0133

Munster, Pamela, Nicholas Iannotti, Daniel C. Cho, John M. Kirkwood, Liza C. Villaruz, Geoffrey T. Gibney, F Stephen Hodi, et al. “Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.” Cancer Res Commun 4, no. 3 (March 13, 2024): 785. https://doi.org/10.1158/2767-9764.CRC-24-0133.

Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, et al. Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Res Commun. 2024 Mar 13;4(3):785.

Munster, Pamela, et al. “Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.” Cancer Res Commun, vol. 4, no. 3, Mar. 2024, p. 785. Pubmed, doi:10.1158/2767-9764.CRC-24-0133.

Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O’Day S. Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Res Commun. 2024 Mar 13;4(3):785.